Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1056634-68-4
Molecular formula
C23H22N6O2
Molecular weight
414.5 g/mol
Drug class
Janus kinase 1/2 and activin A receptor type 1 (ACVR1/ALK2) inhibitortargeted myelofibrosis therapy
Mechanism of action
Inhibits wild-type JAK1 and JAK2 and mutant JAK2 V617F, reducing cytokine-driven JAK-STAT signalling. It also inhibits ACVR1/ALK2, reducing hepcidin expression and increasing iron availability for erythropoiesis, which is relevant to its effect on anaemia.
Indications / reported uses
Treatment of adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis after polycythaemia vera or essential thrombocythaemia, in patients with anaemia
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Momelotinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Momelotinib Permitted Daily Exposure (PDE) report (the Momelotinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Momelotinib Occupational Exposure Limit (OEL) report (the Momelotinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.